NovaBiotics Ltd is a biotechnology company focused on the design, development and application of novel antimicrobials to treat economically and clinically significant infectious conditions and diseases for which there are currently no effective, safe or resistance-free treatments. The first application of this technology will be a topical treatment for nail fungus, NP213.
NovaBiotics is based in Aberdeen and was founded in 2004. Its unique technology has already demonstrated enhanced efficacy, safety and bioavailability over current and emerging competition as well as the potential for a fast-track route to market and revenue initially through its first application.
Nail fungus provides a significant but very poorly met global market. This condition affects in order of 25% of the global population and has a total potential market value in excess of £2.5bn. The Company is in the latter stages of preclinical development for NP213 and will enter clinical trials in 2008.
The platform technology has the potential to expand into larger anti-infective markets. In particular, life-threatening invasive fungal infections, MRSA, acne and the respiratory infections associated with cystic fibrosis.
Most Promising New Life Science Company in Scotland, 2005
Award presented at the Scottish Enterprise Life Science Dinner February 9th, 2006
Winners of the Sir Ian Wood award for inovation 2006
Award presented at the Grampian Business Awards June, 2006
|
